Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter
A look at M&A and alliance activity across the medical device and in vitro diagnostics industries, July-September 2020
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
You may also be interested in...
Dealmaking Quarterly Statistics, Q1 2023
During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.
Deals In Depth: April 2023
Six $1bn+ alliances were penned in April. Topping the list was a potential $2.55bn multi-year deal between Proxygen and Merck to jointly identify and develop molecular glue degraders against multiple therapeutic targets. The collaboration will allow Proxygen to leverage its platform and advance Merck's understanding in molecular glue degraders to open new avenues in the pursuit of novel therapeutics.
Financing Quarterly Statistics, Q1 2023
During Q1, biopharmas brought in an aggregate $13.6bn in financing and device company fundraising totaled $1.8bn; while in vitro diagnostic firms and research tools players raised $753m.